0001209191-23-033681.txt : 20230602
0001209191-23-033681.hdr.sgml : 20230602
20230602161247
ACCESSION NUMBER: 0001209191-23-033681
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230531
FILED AS OF DATE: 20230602
DATE AS OF CHANGE: 20230602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alam Kamran
CENTRAL INDEX KEY: 0001793412
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 23988824
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE, SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-31
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001793412
Alam Kamran
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, STE 1430
DALLAS
TX
75247
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-05-31
4
A
0
6230
A
291042
D
Represents a performance restricted stock unit ("PRSU") award. The PRSUs were awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The PRSUs covered by this report vested upon certification.
Each PRSU represented a contingent right to receive one share the Issuer's common stock.
/s/ Kamran Alam
2023-06-02